Eepsita Priyadarshini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eepsita Priyadarshini has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ajith Manayil Parambil
Nanotechnology Centre Centre for Energy and Environmental Technologies VŠB–Technical University of Ostrava Ostrava‐Poruba Czech Republic
1 shared publication - Anuj Kumar Tomar
School of Environmental Sciences, Jawaharlal Nehru University, New Delhi, India
1 shared publication - Chuxiao Shao
School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, People’s Republic of China
1 shared publication Dravin Pratap Singh
Department of Biomedical Sciences, School of Biosciences and Technology, Galgotias University, Greater Noida, India
1 shared publicationEkta Chauhan
Department of Microbiology, Hemvati Nandan Bahuguna Garhwal University, Srinagar, India
1 shared publicationH. B. Bohidar
School of Physical Sciences, Jawaharlal Nehru University, New Delhi, India
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Biotechnology for Sustainable Materials
- Vol. 3 (1) , 15
Synergistic integration of plant-waste derived bioenzymes and nanozymes for advanced pesticide remediation: a green-nano roadmap
- 6 October 2026
- Published by Springer Nature in Biotechnology for Sustainable Materials
- Vol. 3 (1) , 15
Open AccessSynergistic integration of plant-waste derived bioenzymes and nanozymes for advanced pesticide remediation: a green-nano roadmap
- Open Access
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-21
Targeting ESKAPE pathogens with ZnS and Au@ZnS Core–Shell nanoconjugates for improved biofilm control
The escalating prevalence of antibiotic-resistant infections and implant-related complications caused by biofilm-forming pathogens from the ESKAPE group, as identified by the World Health Organization (WHO), underscores the urgent need for innovative anti-biofilm strategies. Their occurrence on medical implants & prosthetic devices, as well as nosocomial infections in co-morbid patients, has become a global concern in the healthcare sector. In response, we investigated the efficacy of as-synthesized ZnS quantum dots (ZnS QD) and novel Au@ZnS nanoconjugates (Au@ZnS NC) against a spectrum of ESKAPE pathogens. The present study aimed to elucidate their antibacterial and anti-biofilm efficacy, focusing on Acinetobacter baumannii, Enterobacter cloacae, Staphylococcus epidermidis, Enterococcus faecium, Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus faecalis, Staphylococcus aureus and Enterobacter aerogenes pathogens. The novel synthesis and application of ZnS QD and Au@ZnS core-shell NC demonstrate exceptional anti-biofilm efficacy, stability, and solubility in aqueous environments. Utilizing minimum inhibitory concentration (MIC) assays, tube dilution, and biofilm formation assay, we noticed a significant reduction in biofilm formation and extracellular polymeric substances (EPS) production upon treatment with Au@ZnS NC, even at low concentrations. Further investigations, including cell permeability assay, reactive oxygen species analysis, and comet analysis, demonstrated that the Au@ZnS NC induced oxidative stress, destabilizing cell structure, macromolecule destruction, and DNA strand breakage. Notably, Au@ZnS nanoconjugates effectively inhibited biofilm formation within 24 h across all tested strains, outperforming ZnS quantum dots. This research highlights the potential of Au@ZnS nanoconjugates to revolutionize infection control on medical devices and implants, offering a promising solution to the global healthcare challenge posed by biofilm-forming pathogens as we also observed minimal bacterial colonization on Au@ZnS treated urinary catheters.
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-21
Open AccessTargeting ESKAPE pathogens with ZnS and Au@ZnS Core–Shell nanoconjugates for improved biofilm control
The escalating prevalence of antibiotic-resistant infections and implant-related complications caused by biofilm-forming pathogens from the ESKAPE group, as identified by the World Health Organization (WHO), underscores the urgent need for innovative anti-biofilm strategies. Their occurrence on medical implants & prosthetic devices, as well as nosocomial infections in co-morbid patients, has become a global concern in the healthcare sector. In response, we investigated the efficacy of as-synthesized ZnS quantum dots (ZnS QD) and novel Au@ZnS nanoconjugates (Au@ZnS NC) against a spectrum of ESKAPE pathogens. The present study aimed to elucidate their antibacterial and anti-biofilm efficacy, focusing on Acinetobacter baumannii, Enterobacter cloacae, Staphylococcus epidermidis, Enterococcus faecium, Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus faecalis, Staphylococcus aureus and Enterobacter aerogenes pathogens. The novel synthesis and application of ZnS QD and Au@ZnS core-shell NC demonstrate exceptional anti-biofilm efficacy, stability, and solubility in aqueous environments. Utilizing minimum inhibitory concentration (MIC) assays, tube dilution, and biofilm formation assay, we noticed a significant reduction in biofilm formation and extracellular polymeric substances (EPS) production upon treatment with Au@ZnS NC, even at low concentrations. Further investigations, including cell permeability assay, reactive oxygen species analysis, and comet analysis, demonstrated that the Au@ZnS NC induced oxidative stress, destabilizing cell structure, macromolecule destruction, and DNA strand breakage. Notably, Au@ZnS nanoconjugates effectively inhibited biofilm formation within 24 h across all tested strains, outperforming ZnS quantum dots. This research highlights the potential of Au@ZnS nanoconjugates to revolutionize infection control on medical devices and implants, offering a promising solution to the global healthcare challenge posed by biofilm-forming pathogens as we also observed minimal bacterial colonization on Au@ZnS treated urinary catheters.
- 18 June 2019
- Published by Springer Nature in Applied Nanoscience
- Vol. 10 (1) , 281-291
Multimode sensing of riboflavin via Ag@carbon dot conjugates
- 18 June 2019
- Published by Springer Nature in Applied Nanoscience
- Vol. 10 (1) , 281-291
Multimode sensing of riboflavin via Ag@carbon dot conjugates
- Open Access
- 4 April 2018
- Published by IntechOpen
Quantum Dots-Based Nano-Coatings for Inhibition of Microbial Biofilms: A Mini Review
Infection of implants by microbial biofilm is chiefly caused by Staphylococci, Pseudomonas and Candida species. The growth of microbes by forming biofilms offers them protection from antibiotics, drugs and host defense mechanisms. The eradication of biofilms from implants and medical devices is difficult because of the protection by the biofilm forming pathogenic microbes. Hence, researches are focused on development of antibiofilm materials, which are basically constituted of antimicrobial substances or antimicrobial coatings. Nanomaterial-based coatings offer a promising solution in this regard. Quantum dots (QDs) are the group of semiconductor nanoparticles with high photoluminescent properties compared to conventional organic fluorophores. Thus, drug-conjugated QDs can be a promising alternative for biofilm treatment, and these can serve as excellent alternatives for the mitigation of recalcitrant biomaterial-associated infections caused by resistant strains. Furthermore, their use as antibiofilm coating would avoid the dispersion of antimicrobial agents in the surrounding cells and tissues, thereby minimizing the risks of developing microbial resistivity.
- 4 April 2018
- Published by IntechOpen
Open AccessQuantum Dots-Based Nano-Coatings for Inhibition of Microbial Biofilms: A Mini Review
Infection of implants by microbial biofilm is chiefly caused by Staphylococci, Pseudomonas and Candida species. The growth of microbes by forming biofilms offers them protection from antibiotics, drugs and host defense mechanisms. The eradication of biofilms from implants and medical devices is difficult because of the protection by the biofilm forming pathogenic microbes. Hence, researches are focused on development of antibiofilm materials, which are basically constituted of antimicrobial substances or antimicrobial coatings. Nanomaterial-based coatings offer a promising solution in this regard. Quantum dots (QDs) are the group of semiconductor nanoparticles with high photoluminescent properties compared to conventional organic fluorophores. Thus, drug-conjugated QDs can be a promising alternative for biofilm treatment, and these can serve as excellent alternatives for the mitigation of recalcitrant biomaterial-associated infections caused by resistant strains. Furthermore, their use as antibiofilm coating would avoid the dispersion of antimicrobial agents in the surrounding cells and tissues, thereby minimizing the risks of developing microbial resistivity.